肿瘤干细胞与肺腺癌EGFR-TKI获得性耐药机制的研究进展

摘要
图/表
参考文献(42)
相关文章 (15)

全文: PDF (569 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是目前发病率和死亡率增长最快的恶性肿瘤，其中腺癌表皮生长因子受体（EGFR）突变率在肺癌患者中占比最高，针对此类患者，表皮生长因子受体激酶抑制剂（EGFR-TKI）靶向治疗是其主要治疗手段，可以有效抑制带有EGFR敏感突变的肿瘤细胞的生长。然而获得性耐药严重制约了该类药物的使用。肿瘤干细胞（CSC）是存在于肿瘤组织中的小部分细胞，可促进肿瘤细胞生长、侵袭迁移、多向分化及放化疗耐受等。CSC的特异性靶向与常规靶向治疗相结合，或许可达到稳定缓解或治愈肿瘤的目的。因此本文综述近年来CSC与肺腺癌EGFR-TKI获得性耐药机制的研究进展，为今后的研究提供新策略及方向。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈雨1 陈杰2 李亚军1▲

关键词 ：肿瘤干细胞, 肺腺癌, 表皮生长因子酪氨酸激酶抑制剂, 耐药性

Abstract：Lung cancer is currently the malignant tumor with the fastest increase in morbidity and mortality. Among them, the epidermal growth factor receptor (EGFR) mutation rate of adenocarcinoma accounts for the highest proportion of lung cancer patients. For such patients, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy is its main treatment method, which can effectively inhibit the growth of tumor cells with EGFR sensitive mutations. However, acquired drug resistance severely restricts the use of such drugs. Cancer stem cells (CSC) are small part of cells that exist in tumor tissues, which can promote tumor cell growth, invasion and migration, multidirectional differentiation, and resistance to radiotherapy and chemotherapy. The specific targeting of CSC combined with conventional chemotherapy may achieve the goal of stabilizing remission or curing tumors. Therefore, this article reviews recent research progress in the mechanism of acquired drug resistance of CSC and lung adenocarcinoma EGFR-TKI, and provides new strategies and directions for future research.

Key words： Cancer stem cells Lung adenocarcinoma cancer Epidermal growth factor tyrosine kinase inhibitors Drug resistance

基金资助:国家自然科学基金资助项目（82060544、815604 44）；
贵州省遵义市第一人民医院肿瘤科院士工作站[遵市科合（2017）20]；
贵州省遵义市科技计划项目[遵市科合HZ字（2019）36号]。

通讯作者: ▲通讯作者

引用本文:

陈雨1 陈杰2 李亚军1▲. 肿瘤干细胞与肺腺癌EGFR-TKI获得性耐药机制的研究进展[J]. 中国医药导报, 2022, 19(1): 39-43.
CHEN Yu1 CHEN Jie2 LI Yajun1▲. Research progress on the correlation between tumor stem cells and EGFR-TKI resistance mechanism of lung adenocarcinoma#br#. 中国医药导报, 2022, 19(1): 39-43.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I1/39

[1] Herbst RS，Morgensztern D，Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature，2018，553（7689）：446-454.
[2] Wu SG，Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J]. Mol Cancer，2018，17（1）：38.
[3] Gao J，Li HR，Jin C，et al. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer [J]. Clin Transl Oncol，2019，21（10）：1287-1301.
[4] Chen JA，Riess JW. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors [J]. J Thorac Dis，2020，12（5）：2859-2876.
[5] Karachaliou N，Codony-Servat J，Bracht JWP，et al. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients [J]. Expert Rev Respir Med，2019， 13（10）：1019-1028.
[6] Eun K，Ham SW，Kim H. Cancer stem cell heterogeneity：origin and new perspectives on CSC targeting [J]. BMB Rep，2017，50（3）：117-125.
[7] Najafi M，Mortezaee K，Majidpoor J. Cancer stem cell （CSC） resistance drivers [J]. Life Sci，2019，234：116781.
[8] Macdonagh L，Gray SG，Breen E，et al. Lung cancer stem cells：The root of resistance [J]. Cancer Lett，2016，372（2）：147-156.
[9] Shien K，Toyooka S，Yamamoto H，et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells [J]. Cancer Res，2013，73（10）：3051-3061.
[10] Neuzil J，Stantic M，Zobalova R，et al. Tumour-initiating cells vs. cancer ’stem’ cells and CD133：what’s in the name? [J]. Biochem Biophys Res Commun，2007，355（4）：855-859.
[11] Prabavathy D，Swarnalatha Y，Ramadoss N. Lung cancer stem cells-origin，characteristics and therapy [J]. Stem Cell Investig，2018，5：6.
[12] Shao Y，Lv H，Zhong DS，et al. EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties [J]. Oncol Lett，2018，15（5）：6655-6665.
[13] Hashida S，Yamamoto H，Shien K，et al. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib [J]. Cancer Sci，2015，106（10）：1377-1384.
[14] Kobayashi I，Takahashi F，Nurwidya F，et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells [J]. Biochem Biophys Res Commun，2016，473（1）：125-132.
[15] Hidayat M，Mitsuishi Y，Takahashi F，et al. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer [J]. Bosn J Basic Med Sci，2019，19（4）：355-367.
[16] Huang CP，Tsai MF，Chang TH，et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors [J]. Cancer Lett，2013，328（1）：144-151.
[17] Jiang F，Qiu Q，Khanna A，et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer [J]. Mol Cancer Res，2009，7（3）：330-338.
[18] Okudela K，Woo T，Mitsui H，et al. Expression of the potential cancer stem cell markers，CD133，CD44，ALDH1，and β-catenin，in primary lung adenocarcinoma--their prognostic significance [J]. Pathol Int，2012，62（12）：792-801.
[19] Yao W，Wang L，Huang H，et al. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells [J]. BMC Cancer，2020，20（1）：315.
[20] Arrigoni E，Galimberti S，Petrini M，et al. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer：an overview [J]. Expert Opin Drug Metab Toxicol，2016，12（12）：1419-1432.
[21] Sarkadi B，Ozvegy-Laczka C，Német K，et al. ABCG2 -- a transporter for all seasons [J]. FEBS Lett，2004，567（1）：116-120.
[22] An Y，Ongkeko WM. ABCG2：the key to chemoresistance in cancer stem cells? [J]. Expert Opin Drug Metab Toxicol，2009，5（12）：1529-1542.
[23] Anreddy N，Gupta P，Kathawala RJ，et al. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance [J]. Molecules，2014，19（9）：13848-13877.
[24] Singh S，Trevino J，Bora-Singhal N，et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer [J]. Mol Cancer，2012，11：73.
[25] Chen YJ，Huang WC，Wei YL，et al. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells [J]. PLoS One，2011，6（6）：e21428.
[26] Zhong M，Ma X，Sun C，et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer [J]. Chem Biol Interact，2010，184（3）：431-438.
[27] Garg M. Emerging role of microRNAs in cancer stem cells：Implications in cancer therapy [J]. World J Stem Cells，2015，7（8）：1078-1089.
[28] Wang S，Su X，Bai H，et al. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer （NSCLC） patients with EGFR activating mutation [J]. J Hematol Oncol，2015，8：127.
[29] Han J，Zhao F，Zhang J，et al. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway [J]. Int J Oncol，2016，48（5）：1855-1867.
[30] Chen J，Cui JD，Guo XT，et al. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1 [J]. Cancer Med，2018，7（4）：1394-1403.
[31] Li J，Li X，Ren S，et al. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type [J]. Oncotarget，2014，5（17）：7902-7916.
[32] Zhou G，Zhang F，Guo Y，et al. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1 [J]. Biomed Pharmacother，2017，85：113-119.
[33] Yu F，Liu JB，Wu ZJ，et al. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14 [J]. Cancer Lett，2018， 427：74-84.
[34] Chandimali N，Huynh DL，Zhang JJ，et al. MicroRNA-122 negatively associates with peroxiredoxin-Ⅱ expression in human gefitinib-resistant lung cancer stem cells [J]. Cancer Gene Ther，2019，26（9/10）：292-304.
[35] Jiang J，Feng X，Zhou W，et al. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway [J]. Oncotarget，2016，7（45）：73188-73199.
[36] Shi L，Wang Y，Lu Z，et al. miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop [J]. Oncogene，2017，36（12）：1631-1643.
[37] Yin J，Hu W，Pan L，et al. let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer [J]. Oncol Rep，2019，42（2）：495-508.
[38] Chandimali N，Koh H，Kim J，et al. BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer [J]. Oncol Lett，2020，20（4）：103.
[39] 刘浩，方素萍，陈浩然.从肺癌干细胞角度探讨扶正解毒方药改善EGFR-TKIs获得性耐药[J].中华中医药学刊，1-13.
[40] Cheng H，Ge X，Zhuo S，et al. β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2 [J]. Front Pharmacol，2018，9：1413.
[41] Kwon T，Chandimali N，Huynh DL，et al. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells [J]. Cell Death Dis，2018，9（2）：244.
[42] Wang F，Wang W，Li J，et al. Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling [J]. Oncol Lett，2018，15（1）：109-114.